My Account
About Us
Contact us
الواجهة العربية
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



You must sign in to use this servcie

Feedback - Please use the form below to send your query or comment

You must sign in to use this servcie




Acute treatment of migraine with or without aura.


Ischemic heart disease (eg, angina pectoris); symptoms or findings consistent with ischemic heart disease; coronary artery vasospasm (including Prinzmetal variant angina); significant underlying CV disease; cerebrovascular syndromes (including strokes of any type or transient ischemic attacks); peripheral vascular disease (including ischemic bowel disease); uncontrolled hypertension; hemiplegic or basilar migraine; severe hepatic function impairment; hypersensitivity to any component of the product; within 24 h of treatment with another 5-HT 1 agonist or an ergotamine-containing or ergot-type medication (eg, methysergide).

Adverse reactions:

Cardiovascular Palpitation (at least 1%); coronary artery vasospasm; transient myocardial ischemia; MI; ventricular tachycardia; ventricular fibrillation. CNS Dizziness, somnolence (7%); headache (4%); hypertonia, hypesthesia, paresthesia, vertigo (at least 1%). Dermatologic Sweating (at least 1%). GI Nausea (8%); dry mouth (4%); dyspepsia, dysphagia (eg, throat tightness, difficulty swallowing) (2%). Respiratory Pharyngitis (at least 1%). Miscellaneous Asthenia (10%); pain, tightness, or pressure of chest (4%); stomach pain, cramps, or pressure, abdominal pain or discomfort (2%); back pain, chills (at least 1%).


Ergot derivatives (eg, dihydroergotamine) Risk of vasospastic reactions may be increased. Concomitant use within 24 h of eletriptan is not recommended. Other 5-HT 1 agonists Concomitant use of other 5-HT 1 agonists within 24 h of eletriptan is not recommended. Potent CYP-450 3A4 inhibitors (eg, clarithromycin, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, troleandomycin) Eletriptan should not be used within 72 h of drugs that are potent CYP3A4 inhibitors.


Monitor Symptoms of migraine attack Assess pain location, intensity, duration, and associated symptoms of migraine attack and response to treatment. Pregnancy Category C . Lactation Excreted in breast milk. Children Safety and efficacy not established. Elderly There is an increased t ½ (from about 4.4 to 5.7 h) in the elderly (65 to 93 yr of age). CV/Cardiac events It is recommended that eletriptan not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted based on the presence of risk factors (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, women with surgical or physiological menopause, men older than 40 yr of age). Serious adverse cardiac events, including MI, life-threatening disturbances of cardiac rhythm, and death have been reported within a few hours of administration of a 5-HT 1 agonist. Cerebrovascular events Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported with 5-HT 1 agonists. Hypertensive crisis Elevation in BP, including hypertensive crisis, have been reported with administration of 5-HT 1 agonists.



Dosage and Administration

You must sign in to use this servcie

Technical Description

You must sign in to use this servcie

Forgot your password

sign up

Consultants Corner

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr. Talal Sabouni


Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details